These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9834815)

  • 1. The fine points of end points: phase II trials in lung cancer.
    Gelmon KA
    Ann Oncol; 1998 Oct; 9(10):1045-6. PubMed ID: 9834815
    [No Abstract]   [Full Text] [Related]  

  • 2. Evolution and future perspectives in the treatment of locally advanced non-small cell lung cancer.
    Toschi L; Cappuzzo F; Jänne PA
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix150-5. PubMed ID: 17631569
    [No Abstract]   [Full Text] [Related]  

  • 3. Novuspharma announces preliminary results of phase II trials for BBR 3464.
    Expert Rev Anticancer Ther; 2001 Oct; 1(3):325-6. PubMed ID: 12113097
    [No Abstract]   [Full Text] [Related]  

  • 4. Combined radiation and chemotherapy for unresectable non-small cell lung carcinoma.
    Bleehen NM; Ball D; Belani CP; Bishop J; Douillard JY; Cox JD; Johnson DH; Le Chevalier T; Saunders MI; Shaw E
    Lung Cancer; 1994 Mar; 10 Suppl 1():S19-23. PubMed ID: 8087510
    [No Abstract]   [Full Text] [Related]  

  • 5. State of the art in systemic treatment of lung cancer.
    Giaccone G
    Eur J Cancer; 2001 Oct; 37 Suppl 7():S99-114. PubMed ID: 11888010
    [No Abstract]   [Full Text] [Related]  

  • 6. Pembrolizumab Outperforms Docetaxel for NSCLC.
    Leslie M
    Cancer Discov; 2016 Mar; 6(3):223. PubMed ID: 26811324
    [No Abstract]   [Full Text] [Related]  

  • 7. Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?
    Johnson DH; Arteaga CL
    J Clin Oncol; 2003 Jun; 21(12):2227-9. PubMed ID: 12748243
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeted therapies in lung cancer.
    Besse B; Ropert S; Soria JC
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix135-42. PubMed ID: 17631566
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small cell lung cancer.
    Stewart DJ
    J Natl Cancer Inst; 2008 Mar; 100(6):445-6; author reply 446. PubMed ID: 18334712
    [No Abstract]   [Full Text] [Related]  

  • 10. Second-line chemotherapy for non-small cell lung cancer.
    Ruckdeschel JC
    Chest; 2006 Apr; 129(4):840-2. PubMed ID: 16608927
    [No Abstract]   [Full Text] [Related]  

  • 11. Failing survival advantage in crucial trial, future of Iressa is in jeopardy.
    Twombly R
    J Natl Cancer Inst; 2005 Feb; 97(4):249-50. PubMed ID: 15713955
    [No Abstract]   [Full Text] [Related]  

  • 12. Brigatinib effective in ALK-positive non-small-cell lung cancer.
    Das M
    Lancet Oncol; 2017 Jun; 18(6):e310. PubMed ID: 28506557
    [No Abstract]   [Full Text] [Related]  

  • 13. Platinum-based chemotherapy for inoperable non-small cell lung cancer: a real therapeutic progress?
    Buccheri G
    Lung Cancer; 1994 Jul; 11(1-2):115-7. PubMed ID: 7521731
    [No Abstract]   [Full Text] [Related]  

  • 14. Selection bias, phase II trials, and the FDA accelerated approval process.
    George SL
    J Natl Cancer Inst; 2003 Sep; 95(18):1351-2. PubMed ID: 13130101
    [No Abstract]   [Full Text] [Related]  

  • 15. Taxol in advanced non-small-cell lung cancer: plus Ca change?
    Eisenhauer EA
    J Natl Cancer Inst; 1993 Mar; 85(5):346-7. PubMed ID: 8094465
    [No Abstract]   [Full Text] [Related]  

  • 16. Response rate as an endpoint for evaluating new cytotoxic agents in phase II trials of non-small-cell lung cancer.
    Sekine I; Kubota K; Nishiwaki Y; Sasaki Y; Tamura T; Saijo N
    Ann Oncol; 1998 Oct; 9(10):1079-84. PubMed ID: 9834819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Talactoferrin alpha receives fast-track designation for the treatment of non-small cell lung cancer.
    McBride D
    ONS Connect; 2007 Jan; 22(1):14. PubMed ID: 17393636
    [No Abstract]   [Full Text] [Related]  

  • 18. Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma.
    DeGrendele H
    Clin Lung Cancer; 2003 Sep; 5(2):83-5. PubMed ID: 14596689
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunotherapy drug improves survival of patients with squamous non-small cell lung cancer.
    Printz C
    Cancer; 2015 Oct; 121(20):3562-3. PubMed ID: 26431439
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficient designs for testing new agents and regimens.
    Ardizzoni A
    Chest; 1996 May; 109(5 Suppl):83S-86S. PubMed ID: 8635394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.